前哨淋巴结活检阳性乳腺癌区域淋巴结照射决策的国际专家共识调查
该研究邀请21位国际放射肿瘤学专家(19位完成)对早期乳腺癌前哨淋巴结活检阳性(pN1a)且未行腋窝淋巴结清扫患者的区域淋巴结照射(RNI)决策进行共识评估。结果显示,高风险和低风险病例中专家意见较一致(分别推荐全面RNI或省略RNI),但中间风险场景无明确共识,决策标准多达22种,存在显著异质性。
要点
- 高危pN1(sn)乳腺癌专家倾向于推荐全面区域淋巴结照射。
- 低危pN1(sn)乳腺癌专家倾向于省略区域淋巴结照射。
- 中间风险场景无明确共识,决策标准多样且异质。
核心结论
- 乳腺癌专家对pN1(sn)患者推荐RNI时依赖多种不同标准,导致决策异质性,需修订现行指南与专家建议。
研究设计与样本
- 邀请21位国际放射肿瘤学专家参与基于共识的RNI推荐评估,19位完成。
- 评估场景为早期乳腺癌(cN0)前哨淋巴结活检阳性(pN1a)且未行腋窝淋巴结清扫。
主要发现
- 响应中包含22种不同的决策标准,即使简化治疗选项后决策仍存在显著变异性。
- 高风险和低风险病例中最常达成共识,分别推荐全面RNI或省略RNI。
- 中间风险场景未达成明确共识,反映临床考量和风险因素评估的差异。
临床怎么用
- 对pN1(sn)乳腺癌患者,高危者可考虑全面RNI,低危者可考虑省略RNI。
- 中间风险患者需个体化决策,注意现行指南推荐存在异质性。
局限性
- 样本量较小(19位专家完成评估)。
- 决策场景为简化治疗选项,可能未完全反映真实临床复杂性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to evaluate decision-making patterns among international experts regarding breast cancer regional node irradiation (RNI), using an objective, consensus-driven approach. METHODS: Twenty-one international radiation oncology experts were invited to participate in a consensus-based evaluation of RNI recommendations. Participants provided responses to clinical scenarios involving early-stage breast (cN0) cancer with sentinel lymph node biopsy (SNLB)-positive findings (pN1a) without completion axillary lymph node dissection (ALND). Decision-making parameters, including patient age, tumour characteristics, and biological risk factors were analysed. FINDINGS: Of the 21 experts, 19 completed the evaluation. Responses included 22 different decision-making criteria and demonstrated considerable variability in decision-making, even after simplifying treatment options. Consensus was most frequently observed in high- and low-risk cases, with comprehensive RNI or omission of RNI being recommended, respectively. However, for intermediate-risk scenarios, no clear agreement was reached reflecting different clinical considerations and assessment of risk factors. INTERPRETATION: Due to many randomised studies investigating different risk factors that do not always coincide, breast cancer experts rely on a wide variety of criteria to recommend RNI for pN1(sn) breast cancer, leading to heterogeneity in decision-making. With this work we aim to raise awareness of this challenge to provoke revision of current guidelines and expert-based recommendations.
引用
- Putora PM, Henke G, Beşe N, et al. What guides regional nodal irradiation in node positive breast cancer following upfront sentinel lymph node biopsy? Radiother Oncol. 2025. PMID: 40695422. doi:10.1016/j.radonc.2025.111055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。